Such as sunitinib, pazopanib is an orally available inhibitor of the tyrosine kinases of several factors including the vascular endothelial growth factor receptors (VEGFR) 1–3, c-KIT, and the platelet-derived growth factor receptors (PDGFR) alpha and beta, and has been approved for advanced soft tissue sarcoma. Here, KIT is linked to soft tissue sarcoma.